SOURCE: IBC Life Sciences

February 08, 2007 09:30 ET

Manufacturing Technologies for Oligonucleotide and Peptide-Based Technologies to Be Addressed at IBC Life Sciences' Annual TIDES® Conference & Exhibition

TIDES® Will Be Held May 20-23, 2007 at the Red Rock Casino, Resort & Spa in Las Vegas, NV

WESTBOROUGH, MA -- (MARKET WIRE) -- February 8, 2007 -- The TIDES Conference and Exhibition is a forum for researchers and executives working in oligonucleotide and peptide technology and product development. This year's event includes 4 keynote presentations, 60 conference sessions and an exhibit hall with 50 companies.

The TIDES keynote presentations will cover the oligonucelotide market landscape and will review current and future delivery technologies for Oligonucleotides:

--  Marvin H. Caruthers, Ph.D., University of Colorado
    The Landscape for the Oligo Market - A Technology Update
--  Mark E. Davis, Ph.D., California Institute of Technology
    The Landscape of Delivery Technologies for Oligonucleotides: Where
    Are We Today, Prospects for the Near Future
The TIDES conference will cover updates on regulatory strategies and products in clinical and preclinical pipelines. Sessions include:
--  Analytical Strategies for Peptides and Oligos
--  Designing Efficient API Manufacturing Processes for Peptides and
--  Development Strategies of Leading Peptides and Oligonucleotides in the
--  Optimization Strategies of Leading Peptides and Oligonucleotides in
    Preclinical Development
IBC's second annual Nucleic Acids Technologies for Research and Diagnostics will run concurrently with TIDES. The conference sessions include quality management systems in IVD manufacturing, as well as a session covering regulated environment's quality management.

This concurrent conference will have two keynote presentations covering new FDA draft guidance on ASRs and IVDMIA and Identifying RNA Sequences in live cells with reactive fluorescent probes:

--  Elizabeth Mansfield, Ph.D., CDRH, FDA
    New FDA Draft Guidances on ASRs and IVDMIA - Impact on the Regulatory
    Environment for Diagnostics
--  Eric T. Kool, Ph.D., Stanford University
    Reactive Fluorescent Probes for Identifying RNA Sequences in Live Cells
The TIDES exhibit hall includes 50 companies involved in the oligonucleotide, peptide therapeutics and diagnostics market. Top sponsors include Avecia Biotechnology, Executive Sponsor; Chemgenes Corporation, Corporate Sponsor; Girindus Solvay Organics, Corporate Sponsor and SAFC Biosciences is a Biopharmaceutical Production Series Sponsor for IBC Life Sciences.

For questions contact IBC Life Sciences, 800.390.4078 or visit the website at To request a press pass to this event, please email

Review the full brochure at

Contact Information